Micrograph News and Research

RSS

Researchers show how nanocellulose form highly robust materials

Cohesion, the ability to keep things together, from the scale of nanoparticles to building sites is inherent to these nanofibrils, which can act as mortar to a nearly infinite type of particles as described in the study.

12 May 2020

Collaborative approach is essential to speed up COVID-19 vaccine candidates, say NIH experts

A harmonized and collaborative approach to the clinical testing, scale-up and distribution of candidate vaccines to prevent COVID-19 is essential, scientific leaders write in a perspective published today in Science.

12 May 2020

No evidence COVID-19 is spread by fecal-oral transmission

A new study published on the preprint server medRxiv* in May 2020 shows that in patients who test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in pharyngeal and fecal samples, the virus persists longer in the fecal samples than in the pharyngeal samples. However, fecal-oral transmission does not appear to occur.

10 May 2020

Neutralizing SARS-CoV-2 via S protein

A new study published on the preprint server bioRxiv* in May 2020 reports on a method to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by destroying its main spike protein, which is responsible for attachment to the host cell membrane.

10 May 2020

Low-molecular-weight drugs could help against COVID-19 says study

Chinese researchers have worked on using existing low molecular weight drugs to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease.

10 May 2020

Study shows COVID-19 vulnerability is highly dependent on host genetic architecture

A new US study available on the preprint server medRxiv reveals certain genetic variations that are associated with infection susceptibility and diverse clinical presentation of coronavirus disease (COVID-19) – including asymptomatic cases and severe forms of the disease in younger patients.

10 May 2020

Predicting the dose for repurposing nitazoxanide in COVID-19

A new study published on the preprint server medRxiv in May 2020 reports a model that could help evolve appropriate dosage protocols for future clinical trials of the repurposed drug nitazoxanide in COVID-19 prevention and treatment. The researchers say, “It was possible to achieve plasma and lung tizoxanide concentrations, using proven safe doses of nitazoxanide, that exceed the EC90 for SARS-CoV-2.”

7 May 2020

The effect of weather on COVID-19 infection rate

Viral epidemics are nothing new in human history. Several viruses circulate freely every year among human beings, causing seasonal outbreaks of disease and death, such as the seasonal flu. A new study published on the preprint server medRxiv* reports that temperature plays a significant role in the growth of the ongoing COVID-19 pandemic.

6 May 2020

SARS-CoV-2 in wastewater and rivers

A new study published on the preprint server medRxiv in May 2020 shows that while the virus causing COVID-19 may be present in wastewater and rivers, the biological agent is typically devoid of vitality and unable to cause active infection. This should provide some relief to public health authorities in their quest to contain the virus.

6 May 2020

How do betacoronaviruses evolve?

Researchers have worked on the evolution of the pathogenic strains of the betacoronaviruses including the SARS CoV-2 that has caused the COVID-19 pandemic.

6 May 2020

SARS-CoV-2 genome shows mutation hotspots and type-specific distribution

Now, a new study published on the preprint server bioRxiv reports on a large scale analysis of SARS-CoV-2 genomes and reveals a clonal geo-distribution and rich genetic variations.

5 May 2020

Cat coronavirus drug shows promise for treatment of COVID-19

“They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals (cats),” writes the team. “The work here lays the framework for their use in human trials for the treatment of COVID-19.”

5 May 2020

Uncovering immune cell reactions in COVID-19

A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.

4 May 2020

New information on viral antigens could improve COVID-19 testing

Researchers in France and China have characterized antibody responses to a wide range of antigens present on severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) among patients with coronavirus disease 2019 (COVID-19).

4 May 2020

Study reveals variable sites in novel coronavirus SARS-CoV-2

Understanding the varying aggressiveness of SARS-CoV-2 may provide valuable data to trace its spread across populations. In the study, published on the preprint server BioRxiv, the researchers traced amino acid variants that possess high frequency in Europe, particularly in Italy, one of the hardest-hit countries.

4 May 2020

Research detects a more dangerous SARS-CoV-2 mutation

A new study published on the preprint server bioRxiv in May 2020 reports the setting up of a system to help track new mutations in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is behind the current COVID-19 pandemic. This will help analyze mutations to find and track the spread of those that are most likely to increase the pathogenicity of the virus, either by making it easier to transmit or by enhancing its resistance to treatment.

4 May 2020

New clinical trial to assess whether hypertension drug may reduce COVID-19 severity

Researchers at University of California San Diego School of Medicine have launched a clinical trial to investigate whether a drug approved for treating high blood pressure, heart failure and diabetic kidney disease might also reduce the severity of COVID-19 infections, lowering rates for intensive care unit admissions, the use of mechanical ventilators and all-cause mortality.

30 Apr 2020

Testing sewage could be useful in monitoring COVID-19 circulation in the population

Researchers in Italy have demonstrated the potential value of sewage system monitoring for studying trends in the circulation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Apr 2020

Remdesivir shows powerful activity against SARS-CoV-2 in Vitro

Remdesivir is an antiviral first developed by Gilead in 2014 as a treatment for Ebola and Marburg viruses. However, scientists explored its possibilities as a broad-spectrum drug when it proved effective against SARS-CoV and MERS-CoV, coronaviruses which were responsible for earlier outbreaks.

30 Apr 2020

Coronaviruses represent a source of pandemic viruses

In a new paper published on the preprint journal bioRxiv in April 2020, researcher T. Konishi argues that the coronavirus family is a constellation of pandemic pathogens, that includes the currently spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2020